Caris Life Sciences (NASDAQ:CAI) Shares Gap Down – What’s Next?

Caris Life Sciences, Inc. (NASDAQ:CAI) shares gapped down prior to trading on Thursday. The stock had previously closed at $33.22, but opened at $27.18. Caris Life Sciences shares last traded at $26.7540, with a volume of 1,211,277 shares traded.

Caris Life Sciences News Roundup

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Third-quarter revenue rose 27% year over year to $275.4 million, driven by molecular profiling services. Caris raised its 2026 revenue guidance to $1.04–$1.05 billion, implying 28%–29% growth. Caris Q3 results and guidance
• Positive Sentiment: Adjusted earnings of $0.05 per share beat the $0.03 consensus estimate, though they were below the $0.08 reported a year earlier. Q3 earnings and revenue estimates
• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and $38 price target, which the report described as 45.5% above the then-current share price. BTIG Research rating
• Negative Sentiment: Net income fell 37% year over year as expenses increased. The earnings-per-share decline versus last year may temper enthusiasm about the revenue growth and raised outlook. Q3 income and outlook report

Wall Street Analyst Weigh In

A number of analysts have commented on CAI shares. Evercore restated an “outperform” rating and issued a $26.00 price target on shares of Caris Life Sciences in a research report on Thursday, August 6th. UBS Group set a $38.00 price target on shares of Caris Life Sciences in a report on Thursday. Weiss Ratings lowered shares of Caris Life Sciences from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, October 2nd. BTIG Research reissued a “buy” rating and issued a $38.00 price objective on shares of Caris Life Sciences in a research note on Thursday. Finally, Wall Street Zen upgraded Caris Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Eight equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Caris Life Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.91.

Caris Life Sciences Price Performance

The company has a debt-to-equity ratio of 0.66, a quick ratio of 4.88 and a current ratio of 5.53. The firm has a fifty day simple moving average of $29.52 and a two-hundred day simple moving average of $21.74. The firm has a market cap of $7.37 billion, a PE ratio of 72.65 and a beta of 0.71.

Caris Life Sciences (NASDAQ:CAI) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.02. Caris Life Sciences had a return on equity of 18.77% and a net margin of 10.62%. The business had revenue of $275.36 million for the quarter. During the same period last year, the company earned $0.08 earnings per share. The firm’s revenue was up 27.0% on a year-over-year basis. Equities analysts predict that Caris Life Sciences, Inc. will post 0.13 EPS for the current fiscal year.

Insider Activity at Caris Life Sciences

In other news, President David Spetzler sold 478,000 shares of Caris Life Sciences stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $24.86, for a total value of $11,883,080.00. Following the completion of the transaction, the president owned 1,052,083 shares in the company, valued at approximately $26,154,783.38. The trade was a 31.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Brian J. Brille sold 400,000 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $30.33, for a total value of $12,132,000.00. Following the transaction, the insider directly owned 230,303 shares in the company, valued at approximately $6,985,089.99. This represents a 63.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 1,004,712 shares of company stock valued at $27,205,419. Insiders own 50.00% of the company’s stock.

Institutional Investors Weigh In On Caris Life Sciences

Institutional investors have recently made changes to their positions in the company. Braidwell LP raised its position in Caris Life Sciences by 3.1% in the 2nd quarter. Braidwell LP now owns 8,256,032 shares of the company’s stock worth $147,122,000 after purchasing an additional 246,585 shares during the period. PointState Capital LP purchased a new stake in shares of Caris Life Sciences in the second quarter worth approximately $121,690,000. BlackRock Inc. purchased a new stake in shares of Caris Life Sciences in the second quarter worth approximately $98,666,000. Canada Pension Plan Investment Board bought a new stake in shares of Caris Life Sciences during the 2nd quarter worth approximately $24,502,000. Finally, Amundi lifted its position in shares of Caris Life Sciences by 5,709.5% during the second quarter. Amundi now owns 1,218,364 shares of the company’s stock worth $21,711,000 after purchasing an additional 1,197,392 shares during the last quarter.

About Caris Life Sciences

Caris Life Sciences is a biotechnology and precision-medicine company that uses molecular profiling and artificial intelligence to support cancer diagnosis, treatment selection and drug development. The company analyzes tumor and blood samples to identify genomic, molecular and immune characteristics that may help physicians better understand a patient’s disease and select targeted therapies.

Its offerings include comprehensive tumor profiling, liquid-biopsy testing and data-driven clinical decision-support tools.